Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00XWB
|
||||
Former ID |
DIB001382
|
||||
Drug Name |
F-15845
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Angina pectoris [ICD9: 413; ICD10:I20] | Phase 1 | [548229] | ||
Company |
Pierre Fabre SA
|
||||
Structure |
Download2D MOL |
||||
Formula |
C20H26BrNO2S2
|
||||
CAS Number |
CAS 470454-73-0
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Sodium channel protein type 5 subunit alpha | Target Info | Inhibitor | [531108], [532635] | |
KEGG Pathway | Adrenergic signaling in cardiomyocytes | ||||
PathWhiz Pathway | Muscle/Heart Contraction | ||||
Reactome | Interaction between L1 and Ankyrins | ||||
References | |||||
Ref 531108 | Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol. 2010 Sep;161(1):79-91. | ||||
Ref 532635 | A rare loss-of-function SCN5A variant is associated with lidocaine-induced ventricular fibrillation. Pharmacogenomics J. 2014 Aug;14(4):372-5. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.